Market Place
Sourcing Support
Metabolic drug developer HighTide Therapeutics eyes $36M raise with HK IPO
14 Dec 2023 //
ENDPTS
HighTide Therapeutics Raises $107 Million in Series C/C+ Financing
05 Jan 2023 //
PR NEWSWIRE
HighTide Therapeutics rides NASH R&D wave with a $107M raise
05 Jan 2023 //
ENDPTS
HighTide Therapeutics Announces Presentations at The Liver Meeting® 2022
25 Oct 2022 //
BUSINESSWIRE
HighTide Therapeutics Appoints Daniel Ripley as SVP Business Development
20 Oct 2022 //
BUSINESSWIRE
HighTide Announces Enrollment in PII Study Evaluating HTD1801
30 Aug 2022 //
BUSINESSWIRE
HighTide Therapeutics Begins Dosing in PII Study Evaluating HTD1801
28 Apr 2022 //
BUSINESSWIRE
HighTide Appoints Myleen Leoncavallo as SVP RA and QA
31 Mar 2022 //
BUSINESSWIRE
HighTide Tx End-of-Phase 2 Meeting with FDA; to Proceed to Phase 3 for HTD1801
22 Feb 2022 //
BUSINESSWIRE
HighTide Therapeutics to Present New PSC and NASH Clinical Data at AASLD 2021
28 Oct 2021 //
BUSINESSWIRE
HighTide’s HTD1801 Demonstrates improved effects in Diabetic NASH Patients
21 Sep 2021 //
BUSINESSWIRE
HighTide Announces the Presentation of Results of Phase 2 Study of HTD1801
21 Jun 2021 //
BUSINESSWIRE
HighTide Announces NMPA Approval for HTD1801 Clinical Trial in China
27 May 2021 //
BUSINESSWIRE
HighTide to Present Phase 2 Results of HTD1801 in NASH Patients
16 Dec 2020 //
BUSINESSWIRE
HighTide to Present Phase 2 Results of HTD1801 in NASH Patients
16 Dec 2020 //
BUSINESSWIRE
HighTide Therapeutics to Present at HC Wainwright’s 4th Annual NASH
01 Oct 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.